Business Context and Reporting Period
This Form 8-K Current Report was filed by IRADIMED CORPORATION on April 1, 2016. The filing addresses a significant regulatory event regarding the Company's 510(k) application for its MRidium 3860+ infusion pump and announces the upcoming release of first-quarter 2016 financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are scheduled to be disclosed in the first-quarter 2016 financial results, which the Company plans to release before the market opens on April 29, 2016.
Material Changes and Regulatory Events
- FDA Application Denial: The Company received a letter dated March 23, 2016, from the FDA denying its 510(k) application with a finding of non-substantial equivalence.
- Reason for Denial: The denial was due to a lack of human factors data validating the Dose Errors Reduction System (DERS). Specifically, two of fifty-six test subjects unintentionally bypassed the DERS feature, avoiding hard dose limits.
- Next Steps: The Company intends to appeal this determination to a higher level within the FDA and anticipates submitting the appeal by April 23, 2016.
Outlook, Management Commentary, and Risks
- Financial Results: The Company will release Q1 2016 results on April 29, 2016, followed by a conference call at 11:00 a.m. Eastern Time.
- Regulatory Risk: The denial of the 510(k) application poses a risk to the commercialization of the MRidium 3860+ infusion pump until the appeal is resolved or a new application with sufficient data is submitted.
- Management Action: Management is actively pursuing an appeal to overturn the FDA's finding of non-substantial equivalence.
Investor Verification Checklist
- Verify the status of the FDA appeal expected to be submitted by April 23, 2016.
- Review the Q1 2016 financial results released on April 29, 2016, for any impact of the regulatory delay on revenue or expenses.
- Monitor subsequent communications regarding the resubmission of the 510(k) application with additional human factors data.
- Assess the potential timeline for market approval of the MRidium 3860+ infusion pump given the current regulatory setback.